Progress in the discovery of factor Xa inhibitors

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 2, 2006, Pages 119-145

  Casimiro Garcia, Agustin ^a   Dudley, Danette A ^a   Heemstra, Ronald J ^a   Filipski, Kevin J ^a   Bigge, Christopher F ^a   Edmunds, Jeremy J ^a  

^a PFIZER INC   (United States)

Author keywords

Anticoagulant; Antithrombotic; Factor Xa inhibitor; Serine protease

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 2 PYRROLIDONE DERIVATIVE; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ACRYLAMIDE DERIVATIVE; ANTICOAGULANT AGENT; BAY 597939; BENZAMIDE DERIVATIVE; BENZAMIDINE DERIVATIVE; BENZOXAZINONE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBAMIC ACID DERIVATIVE; EMD 495235; FXV 673; ISOXAZOLINE DERIVATIVE; KETENE DERIVATIVE; KETOPIPERAZINE DERIVATIVE; LY 517717; N [2 (5 AMIDINO 2 HYDROXYPHENOXY) 3,5 DIFLUORO 6 [3 (1 METHYL 1H 2 IMIDAZOLIN 2 YL)PHENOXY] 4 PYRIDINYL] N METHYLGLYCINE; OTAMIXABAN; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE 1 OXIDE; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; RAZAXABAN; RPR 200095; RPR 200443; RPR 209685; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTERY THROMBOSIS; CAROTID ARTERY THROMBOSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EX VIVO STUDY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VENOUS THROMBOEMBOLISM; X RAY CRYSTALLOGRAPHY;

EID: 33144474702     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.2.119     Document Type: Review

References (89)

1. American Heart Association: Heart Disease and Stroke Statistics - 2005 Update. Dallas, Texas. American Heart Association (2004).
2. LEADLEY RJ: Coagulation Factor Xa inhibition: biological background and rationale. Curr. Top. Med. Chem. (2001) 1:151-159.
3. WALENGA JM, JESKE WP, HOPPENSTEADT D, FAREED J: Factor Xa inhibitors: today and beyond. Curr. Opin. Investig. Drugs (2003) 4:272-281.
4. WIELAND HA, LAUX V, KOZIAN D, LORENZ M: Approaches in anticoagulation: rationales for target positioning. Curr. Opin. Investtg. Drugs (2003) 4:264-271.
5. AL-OBEIDI F, OSTREM JA: Factor Xa inhibitors. Expert Opin. Ther. Patents (1999) 9:931-953.
6. LAM PY, CLARK CG, LI R et al.: Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable Factor Xa inhibitors as novel anticoagulants. J. Med. Chem. (2003) 46:4405-4418.
7. QUAN ML, SMALLHEER JM: The race to an orally active Factor Xa inhibitor: recent advances. Curr. Opin. Drug Disc. Dev. (2004) 7:460-469.
8. NAGAHARA T, YOKOYAMA Y, INAMURA K et al.: Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation Factor Xa inhibitors. J. Med. Chem. (1994) 37:1200-1207.
9. DYKE CK, BECKER RC, KLEIMAN NS et al.: First experience with direct Factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation (2002) 105:2385-2391.
10. ALEXANDER JH, DYKE CK, YANG H et al.: Initial experience with Factor Xa inhibition in percutaneous coronary intervention: the XaNADU-PIC Pilot. J. Thromb. Haemost. (2004) 2:234-241.
11. PINTO DJ, ORWAT MJ, WANG S et al.: Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro- 2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC-423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation Factor Xa. J. Med. Chem. (2001) 44:566-578.
12. WONG PC, PINTO DJ, KNABB RM: Nonpeptide Factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc. Drug Rev. (2002) 20:137-152.
13. QUAN ML, LAM PY, HAN Q et al.: Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3- trifluoromethyl-N-[2-fluoro-4-[(2′-dimethylaminomethyl) imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable Factor Xa inhibitor. J. Med. Chem. (2005) 48:1729-1744.
14. LASSEN MR. DAVIDSON BL, GALLUS A et al.: A Phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery - on behalf of the razaxaban investigators. Blood (2003) 102: Abst 41.
15. ROEHRIG S, STRAUB A, POHLMANN J et al.: Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor. J. Med. Chem. (2005) 48:5900-5908.
16. TURPIE AC, FISHER WD, BAUER K et al.: An oral, direct Factor Xa inhibitor - BAY 59-7939 - for prophylaxis against aenous ahromboembolism after total knee replacement: a dose-ranging study. International Society for Thrombosis and Hacmostasis. Sydney, Australia (2005) Abstract 02573.
17. CZEKAJ M, KLEIN SI, GUERTIN KR et al.: Optimization of the β-aminoester class of Factor Xa inhibitors. Part 1: P4 and side-chain modifications for improved in vitro potency. Bioorg. Med. Chem. Lett. (2002) 12:1667-1670.
18. GUERTIN KR, GARDNER CJ, KLEIN SI et al.: Optimization of the β-aminoester class of Factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent in vivo anticoagulant activity. Bioorg. Med. Chem. Lett. (2002) 12:1671-1674.
19. CHU V, BROWN K, COLUSSI D et al.: Pharmacological characterization of a novel Factor Xa inhibitor, FXV673. Thromb. Res. (2001) 103:309-324.
20. REBELLO SS, BENTLEY RG, MORGAN SR et al.: Antithrombotic efficacy of a novel Factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br. J. Pharmacol. (2001) 133:1190-1198.
21. REBELLO SS, KASIEWSKI CJ, WANG W et al.: Role of short-term inhibition of Factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs. J. Cardiovasc. Pharmacol. (2001) 38:288-297.
22. NUTESCU EA, WITTKOWSKY AK: Direct thrombin inhibitors for anticoagulation. Ann. Pharmacother. (2004) 38:99-109.
23. GONG Y, BECKER M, CHOI-SLEDESKI YM et al.: Solid-phase parallel synthesis of azarene pyrrolidinones as Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:1033-1036.
24. CHOI-SLEDESKI YM, KEARNEY R, POLI G et al.: Discovery of an orally efficacious inhibitor of coagulation Factor Xa which incorporates a neutral P1 ligand. J. Med. Chem. (2003) 46:681-684.
25. BETZ A: Recent advances in Factor Xa inhibitors. Expert Opin. Ther. Patents (2001) 11:1007-1017.
26. MAIGNAN S, GUILLOTEAU JP, CHOI-SLEDESKI YM et al.: Molecular structures of human Factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. J. Med. Chem. (2003) 46:685-690.
27. HE W, HANNEY B, MYERS MR et al.: Benzimidazoles and isosteric compounds as potent and selective Factor Xa inhibitors. Bioorg. Med. Chem Lett. (2002) 12:919-922.
28. PAULS HW, EWING WR: The design of competitive, small molecule inhibitors of coagulation Factor Xa. Curr. Top. Med. Chem. (2001) 1:83-100.
29. GOULD WR, LEADLEY RJ: Recent advances in the discovery and development of direct coagulation Factor Xa inhibitors. Curr. Pharm. Design (2003) 9:2337-2347.
30. NAZARÉ M, MATTER H, KLINGLER O et al.: Novel Factor Xa inhibitors based on a benzoic acid scaffold incorporating a neutral P1 ligand. Bioorg. Med. Chem. Lett. (2004) 14:2801-2805.
31. MATTER H, WILL DW, NAZARÉ M et al.: Structural requirements for Factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. J. Med. Chem. (2005) 48:3290-3312.
32. NAZARÉ M, ESSRICH M, WILL DW et al.: Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents. Bioorg. Med. Chem. Lett. (2004) 14:4191-4195.
33. NAZARÉ M, WILL DW, MATTER H et al.: Probing the subpockets of Factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. J. Med. Chem. (2005) 48:4511-4525.
34. NAZARÉ M, ESSRICH M, WILL DW et al.: Novel Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand. Bioorg. Med. Chem Lett. (2004) 14:4197-4201.
35. ROEHRIG S, STRAUB A, POHLMANN J et al.: Discovery of the novel antithrombotic agent BAY 59-7939, an orally active, direct Factor Xa inhibitor. 228th ACS National Meeting. Philadelphia, USA (2004) MEDI-156.
36. PERZBORN E, STRASSBURGER J, POHLMANN J et al.: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. (2005) 3:514-521.
37. KUBITZA D, BECKA M, WENSING G et al.: Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects. Blood (2003) 102:811a.
38. KUBITZA D, BECKA M, WENSING G et al.: Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects. Blood (2003) 102:813a.
39. LIGHT DR, GUILFORD WJ: Discovery of the Factor Xa inhibitor, ZK 807834 (CI-1031). Curr. Top. Med. Chem. (2001) 1:121-136.
40. ARNAIZ DO, ZHAO Z, LIANG A et al.: Design, synthesis, and in vitro biological activity of indole-based Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:957-961.
41. ZHAO Z, ARNAIZ DO, GRIEDEL B et al.: Design, synthesis, and in vitro biological activity of benzimidazole based Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:963-966.
42. WU S, GUILFORD WJ, CHOU Y-L et al.: Design and synthesis of aminophenol-base Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1307-1310.
43. CHOU Y-L, DAVEY DD, EAGEN KA et al.: Structure-activity relationships of substituted benzothiophene-anthranilamide Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:507-511.
44. ADLER M, KOCHANNY MJ, YE B et al.: Crystal structures of two potent nonamidine inhibitors bound to Factor Xa. Biochemistry (2002) 41:15514-15523.
45. QUAN ML, WEXLER RR: The design and synthesis of noncovalent Factor Xa inhibitors. Curr. Top. Med. Chem. (2001) 1:137-149.
46. WONG PC, WATSON CA, CRAIN EJ et al.: Antithrombotic effects of razaxaban, an orally-active Factor Xa inhibitor, in rabbit models of thrombosis. Blood (2003) 102: Abst 3011.
47. QUAN ML, ELLIS CD, HE MY: Nonbenzamidine tetrazole derivatives as Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:369-373.
48. QUAN ML, ELLIS CD, HE MY et al.: Nonbenzamidine isoxazoline derivatives as Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:1023-1028.
49. SHI Y, SITKOFF D, ZHANG J et al.: Ketene aminals based lactam derivatives as novel class of orally bioavailable FXa inhibitors. 226th ACS National Meeting. New York, USA (2003) MEDI-81.
50. HAGINOYA N, KOBAYASHI S, KOMORIYA S et al.: Orally active Factor Xa inhibitors: 4,5,6,7-tetrahydrothiarzolo[5,4-c]pyridine derivatives. Bioorg. Med. Chem. Lett. (2004 14:2935-2939.
51. HAGINOYA N, KOBAYASHI S, KOMORIYA S et al.: Synthesis and conformational analysis of a non-amidine Factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element. J. Med. Chem. (2004) 47:5167-5182.
52. HAGINOYA N, KOBAYASHI S, KOMORIYA S et al.: Design, synthesis, and biological activity of non-amidine Factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units. Bioorg. Med. Chem. Lett. (2004) 12:5579-5586.
53. KOMORIYA S, HAGINOYA N, KOBAYASHI S et al.: Design, synthesis, and biological activity of non-basic compounds as Factor Xa inhibitors: SAR study of S1 and aryl binding sites. Bioorg. Med. Chem. Lett. (2005) 13:3927-3954.
54. MENDEL D, MARQUART AL, JOSEPH S et al.: Anthranilamide inhibitors of Factor Xa. 229th ACS National Meeting. San Diego, USA (2005). MEDI-246.
55. BATES SM, WEITZ JI: New anticoagulants: beyond heparin, low-molecular-weight heparin and warfain. Br. J. Pharmacol. (2005) 144:1017-1028.
56. JONES SD, LIEBESCHUETZ JW, MORGAN PJ et al.: The design of phenylglycine containing benzamidine carboxamides as potent and selective inhibitors of Factor Xa. Bioorg. Med. Chem. Lett. (2001) 11:733-736.
57. MASTERS JJ, WEBER WW, FRANCISKOVICH JB et al.: Bicyclic S1-binding constructs in a series of phenyl glycine-based inhibitors of human Factor Xa. 224th ACS National Meeting. Boston, USA (2002) MEDI-284.
58. SHEEHAN SM, MASTERS JJ, WILEY MR et al.: A four component coupling strategy for the synthesis of E-phenylglycinamide-derived non-covalent Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:2255-2259.
59. WILEY MR, SMITH SM, BASTIAN JA et al.: Non-aromatic E-amino acid-derived inhibitors of human FXa. 228th ACS National Meeting. Philadelphia, USA (2004) MEDI-252.
60. WILEY MR, BASTIAN JA, SALL DJ et al.: SAR investigation of heteroatom containing non-arylglycine inhibitors of human fXa. 228th ACS National Meeting. Philadelphia, USA (2004) MEDI-254.
61. SHEEHAN SM, WATSON BM, WILEY MR et al.: 1,2-Aminoethanol-derived non-covalent Factor Xa inhibitors. 226th ACS National Meeting. New York, USA (2003) MEDI-357.
62. MEDERSKI WW, GERMANN M: A general synthesis of 1-aryl carbamoyl-2-alkyl-4-aryl substituted semicarbazides as nonbasic Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:3715-3718.
63. MEDERSKI WW, DORSCH D, ANZALI S et al.: Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation Factor Xa. Bioorg. Med. Chem. Lett. (2004) 14:3763-3769.
64. MEDERSKI WWKR, CEZANNE B, VAN AMSTERDAM C et al.: Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation Factor Xa. Bioorg. Med. Chem. Lett. (2004) 14:5817-5822.
65. CEZANNE B, DORSCH D, MEDERSKI WW et al.: Novel solubilizing S4-residues for Factor Xa inhibitors: synthesis and structure-activity relationships of 1-aryl-2-imino-pyrrolidine and -piperidine derivatives. 228th ACS National Meeting. Philadelphia, USA (2004) MEDI-253.
66. SONG Y, CLIZBE L, BHAKTA C et al.: Design, synthesis, and SAR of substituted acrylamides as Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1511-1515.
67. SONG Y, CLIZBE L, BHAKTA C et al.: Substituted arylamides as Factor Xa inhibitors: improving bioavailability by P1 modification. Bioorg. Med. Chem. Lett. (2002) 12:2043-2046.
68. SONG Y, CLIZBE L, BHAKTA C et al.: Design and synthesis of Factor Xa inhibitors and their prodrugs. Bioorg. Med. Chem. Lett. (2003) 13:297-300.
69. JIA ZJ, WU Y, HUANG W et al.: Design, synthesis, and biological activity of novel non-amidine Factor Xa inhibitors. Part 1: structure-activity relationships of the substituted 1-(2-napthyl)-1H-pyrazole-5-carboxylamides. Bioorg. Med. Chem. Lett. (2002) 12:1651-1655.
70. JIA ZJ, WU Y, HUANG W et al.: 1-(2-Napthyl)-1H-pyrazole-5-carboxylamides as potent Factor Xa inhibitors. Part 2: a survey of P4 motifs. Bioorg. Med. Chem. Lett. (2004) 14:1221-1227.
71. JIA ZJ, WU Y, HUANG W et al.: 1-(2-Napthyl)- 1H-pyrazole-5-carboxylamides as potent Factor Xa inhibitors. Part 3: design, synthesis, and SAR of orally bioavailable benzamidine-P4 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:1229-1234.
72. ZHANG P, ZUCKETT JF, WOOLFREY J et al.: Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1657-1661.
73. ZHANG P. BAO L, ZUCKETT JF et al.: Design, synthesis, and SAR of anthranilamide-based Factor Xa inhibitors incorporating substituted biphenyl P4 motifs. Bioorg. Med. Chem. Lett. (2004) 14:983-987.
74. ZHANG P, BAO L, ZUCKETT JF et al.: Design, synthesis, and SAR of anthranilamide-based Factor Xa inhibitors with improved functional activity. Bioorg. Med. Chem. Lett. (2004) 14:989-993.
75. JIA ZJ, SU T, ZUCKETT JF et al.: N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamides as potent Factor Xa inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:2073-2078.
76. NISHIDA H, MIYAZAKI Y, KITAMURA Y et al.: Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as Factor Xa inhibitor. Chem. Pharm. Bull. (2001) 49:1237-1244.
77. NISHIDA H, MIYAZAKI Y, MUKAIHIRA T et al.: Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a Factor Xa inhibitor II. Substituent effect on biological activities. Chem. Pharm. Bull. (2002) 50:1187-1194.
78. NISHIDA H, MIYAZAKI Y, MUKAIHIRA T et al.: Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as Factor Xa inhibitors III. Effect of ring opening of piperazinone moiery on inhibition. Chem. Pharm. Bull. (2004) 52:459-462.
79. NISHIDA H, MUKAIHIRA T, SAITOH F et al.: Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as Factor Xa inhibitors IV. A series of new derivatives containing a spiro[5H-oxazolo[3,2-a]pyrazine-2(3H), 4′-piperidin]-5-one skeleton. Chem. Pharm. Bull. (2004) 52:406-412.
80. NISHIDA H, MUKAIHIRA T, SAITOH F et al.: Design, synthesis and biological activities of new potent Factor Xa inhibitor. 228th ACS National Meeting. Philadelphia, USA (2004), MEDI-251.
81. DUDLEY DA, BUNKER AM, CHI L et al.: Rational design, synthesis, and biological activity of benzoxazinones as novel Factor Xa inhibitors. J. Med. Chem. (2000) 43:4063-4070.
82. WILLARDSEN JA, DUDLEY DA, CODY WL et al.: Design, synthesis and biological activity of potent and selective inhibitors of blood coagulation Factor Xa. J. Med. Chem. (2004) 47:4089-4099.
83. HIRAYAMA F, KOSHIO H, KATAYAMA N et al.: The discovery of YM-60828: a potent, selective and orally-bioavailable Factor Xa inhibitor. Bioorg. Med. Chem. (2002) 10:1509-1523.
84. SATO K, KAKU S, HIRAYAMA F et al.: Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. Eur. J. Pharmacol. (1998) 352:59-63.
85. SATO K, KAWASAKI T, HISAMICHI N et al.: Antithrombotic effectS of YM-75466 in three thrombosis models in guinea pigs. Eur. J. Pharmacol. (1998) 350:87-91.
86. HIRAYAMA F, KOSHIO H, ISHIHARA T et al.: Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable Factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates. Bioorg. Med. Chem. (2002) 10:2597-2610.
87. HIRAYAMA F, KOSHIO H, KATAYAMA N et al.: Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable Factor Xa inhibitors based on benzothiadiazine-4-one template. Bioorg. Med. Chem. (2003) 11:367-381.
88. KOSHIO H, HIRAYAMA F, ISHIHARA T et al.: Synthesis and biological activity of novel 1,4-diazepane derivatives as Factor Xa inhibitor with potent anticoagulant and antithrombotic activity Bioorg. Med. Chem. (2004) 12:2179-2191.
89. KOSHIO H, HIRAYAMA F, ISHIHARA T et al.: Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as Factor Xa inhibitors. Bioorg. Med. Chem. (2005) 13:1305-1323.